These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3389753)

  • 41. Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Nov; 404():1-303. PubMed ID: 12621514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of cortisone-heparin and cortisone-maltose tetrapalmitate therapies against rodent tumors. I. Biological studies.
    Benrezzak O; Madarnas P; Pageau R; Nigam VN; Elhilali MM
    Anticancer Res; 1989; 9(6):1883-7. PubMed ID: 2627134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selenium inhibition of 1,2-dimethylhydrazine-induced colon carcinogenesis.
    Jacobs MM
    Cancer Res; 1983 Apr; 43(4):1646-9. PubMed ID: 6831412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of the potential chemopreventive agent, hesperetin (citrus flavanone), on 1,2-dimethylhydrazine induced colon carcinogenesis.
    Aranganathan S; Nalini N
    Food Chem Toxicol; 2009 Oct; 47(10):2594-600. PubMed ID: 19632289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
    MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
    Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
    Chan P
    Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity of chemically induced murine colon cancers.
    Belnap LP; Cleveland PH; Colmerauer ME; Barone RM; Pilch YH
    Cancer Res; 1979 Apr; 39(4):1174-9. PubMed ID: 84709
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protective effect of oral Salmonella enteritidis 11RX infection against colon tumor induction by 1,2-dimethylhydrazine in mice.
    Ashman LK; Cook MG; Kotlarski I
    Cancer Res; 1979 Jul; 39(7 Pt 1):2768-71. PubMed ID: 376122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of cortisone-heparin and cortisone-maltose tetrapalmitate therapies against rodent tumors. II. Pathological studies.
    Madarnas P; Benrezzak O; Pageau R; Nigam VN; Elhilali M
    Anticancer Res; 1989; 9(6):1889-95. PubMed ID: 2627135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of maltose tetrapalmitate on tumor vascularization and tumor growth.
    Benrezzak O; Bissonnette E; Madarnas P; Nigam VN
    Anticancer Res; 1989; 9(6):1815-8. PubMed ID: 2483306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical significance of gastrin receptors in human colon cancers.
    Upp JR; Singh P; Townsend CM; Thompson JC
    Cancer Res; 1989 Jan; 49(2):488-92. PubMed ID: 2910467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of 60Co gamma-radiation, misonidazole, and maltose tetrapalmitate in the treatment of Dunning prostatic tumor in the rat.
    Pageau R; Nigam VN; Fisher GJ; Brailovsky CA; Fathi MA; Corcos J; Tahan TW; Elhilali MM
    Int J Radiat Oncol Biol Phys; 1985 Aug; 11(8):1483-7. PubMed ID: 4019272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The antitumour activity of maltose tetrapalmitate compared with other immunoadjuvants, and its effectiveness after tumour surgery.
    El Kappany H; Chopra C; Nigam VN; Brailovsky CA; Elhilali M
    Br J Cancer; 1980 Nov; 42(5):703-11. PubMed ID: 7459208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How can chemoimmunotherapy best be used for the treatment of colon cancer?
    Medina-Echeverz J; Berraondo P
    Immunotherapy; 2012 Dec; 4(12):1787-90. PubMed ID: 23240744
    [No Abstract]   [Full Text] [Related]  

  • 56. Cancer immunotherapy. Part II: New approaches.
    Elias EG
    Md Med J; 1991 Jun; 40(6):525-6. PubMed ID: 1861581
    [No Abstract]   [Full Text] [Related]  

  • 57. Evaluation of dimethylhydrazine induced tumours in mice as a model system for colorectal cancer.
    Haase P; Cowen DM; Knowles JC; Cooper EH
    Br J Cancer; 1973 Dec; 28(6):530-43. PubMed ID: 4131500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapy of colon cancer metastases in rats with the immunostimulant OM-89.
    Lagadec P; Onier N; Bauer J; Tourne S; Jeannin JF
    Anticancer Drugs; 1990 Dec; 1(2):143-7. PubMed ID: 2131046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Active specific immunotherapy and immunochemotherapy in the treatment of lung and colon cancer.
    Hollinshead A
    Semin Surg Oncol; 1991; 7(4):199-210. PubMed ID: 1925251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined-modality oncotherapy with cyclophosphamide (NSC-26271) and radiotherapy: control of murine mastocytoma.
    Schenken LL; Hagemann RF; Burholt DR; Lesher S
    J Natl Cancer Inst; 1976 Oct; 57(4):943-9. PubMed ID: 826650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.